0000950170-23-046504.txt : 20230905 0000950170-23-046504.hdr.sgml : 20230905 20230905173433 ACCESSION NUMBER: 0000950170-23-046504 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230901 FILED AS OF DATE: 20230905 DATE AS OF CHANGE: 20230905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boyle Kevin S. Sr. CENTRAL INDEX KEY: 0001880600 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33038 FILM NUMBER: 231237077 MAIL ADDRESS: STREET 1: C/O ZIOPHARM ONCOLOGY, INC. STREET 2: ONE FIRST AVENUE, PARRIS BLDG 34 CITY: BOSTON STATE: MA ZIP: 02129 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Alaunos Therapeutics, Inc. CENTRAL INDEX KEY: 0001107421 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841475642 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8030 EL RIO STREET CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: (346) 355-4099 MAIL ADDRESS: STREET 1: 8030 EL RIO STREET CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: ZIOPHARM ONCOLOGY INC DATE OF NAME CHANGE: 20050919 FORMER COMPANY: FORMER CONFORMED NAME: EASYWEB INC DATE OF NAME CHANGE: 20010213 4 1 ownership.xml 4 X0508 4 2023-09-01 0001107421 Alaunos Therapeutics, Inc. TCRT 0001880600 Boyle Kevin S. Sr. C/O ALAUNOS THERAPEUTICS, INC. 8030 EL RIO ST. HOUSTON TX 77054 true true false false Chief Executive Officer true Common Stock 2023-09-01 4 S false 68014 0.1403 D 798236 D Represents the sale of shares of Common Stock pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of shares of restricted stock previously granted to the Reporting Person. This sale was effected pursuant to a plan adopted on November 17, 2022 in accordance with Rule 10b5-1 and does not represent a discretionary sale by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.14 to $0.1424, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Melinda Lackey, Attorney-in-Fact 2023-09-05